Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock Has Consensus Target Price of $4.00 According to Analysts

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been given an average rating of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $4.00.

TNYA has been the subject of a number of research reports. Wall Street Zen upgraded Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, September 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday.

Hedge Funds Weigh In On Tenaya Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TNYA. BlackRock Inc. acquired a new stake in Tenaya Therapeutics during the 2nd quarter valued at approximately $2,963,000. Empery Asset Management LP acquired a new position in Tenaya Therapeutics during the 2nd quarter valued at about $2,855,228. Renaissance Technologies LLC raised its stake in Tenaya Therapeutics by 100.6% during the 1st quarter. Renaissance Technologies LLC now owns 3,713,761 shares of the company’s stock valued at $2,571,000 after acquiring an additional 1,862,894 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in Tenaya Therapeutics in the second quarter worth about $1,973,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Tenaya Therapeutics in the 2nd quarter worth approximately $1,150,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Trading Down 1.3%

Shares of Tenaya Therapeutics stock opened at $0.40 on Friday. Tenaya Therapeutics has a twelve month low of $0.36 and a twelve month high of $1.56. The stock has a market capitalization of $90.81 million, a P/E ratio of -0.75 and a beta of 2.87. The business’s fifty day moving average price is $0.58 and its 200 day moving average price is $0.71.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.13). The business had revenue of $1.11 million during the quarter, compared to the consensus estimate of $10.00 million. As a group, sell-side analysts predict that Tenaya Therapeutics will post -0.38 EPS for the current year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.